Guangdong Dongyangguang Pharma

HEC Pharma, officially known as YiChang HEC ChangJiang Pharmaceutical, is a leading Chinese pharmaceutical company and a core subsidiary of the HEC Group. The company is a dominant player in the anti-viral market, primarily through its blockbuster influenza treatment Kewei (oseltamivir phosphate), which holds a significant share of the Chinese market. Beyond its anti-viral franchise, HEC Pharma has expanded its portfolio into chronic disease areas including endocrine and metabolic disorders, cardiovascular diseases, and oncology. The company leverages a robust R&D platform, often in collaboration with its affiliate Sunshine Lake Pharma, to develop both innovative new drugs and high-end generics. Listed on the Hong Kong Stock Exchange, HEC Pharma operates extensive GMP-certified manufacturing facilities and continues to invest in biologics, including insulin analogues and GLP-1 receptor agonists.